CALCIMAR SOLUTION

Država: Kanada

Jezik: angleščina

Source: Health Canada

Aktivna sestavina:

CALCITONIN (SALMON SYNTHETIC)

Dostopno od:

SANOFI-AVENTIS CANADA INC

Koda artikla:

H05BA01

INN (mednarodno ime):

CALCITONIN (SALMON SYNTHETIC)

Odmerek:

200UNIT

Farmacevtska oblika:

SOLUTION

Sestava:

CALCITONIN (SALMON SYNTHETIC) 200UNIT

Pot uporabe:

INTRAMUSCULAR

Enote v paketu:

2ML

Tip zastaranja:

Prescription

Terapevtsko območje:

PARATHYROID AND ANTIPARATHYROID AGENTS

Povzetek izdelek:

Active ingredient group (AIG) number: 0111011001; AHFS:

Status dovoljenje:

APPROVED

Datum dovoljenje:

2006-05-08

Lastnosti izdelka

1
PRODUCT MONOGRAPH
PR
CALCIMAR
®
Synthetic Salmon Calcitonin
Solution, 200 IU / mL
Intramuscular or Subcutaneous Injection
Calcium Regulator
sanofi-aventis Canada Inc
2905 Place Louis-R.-Renaud
Laval, Quebec, H7V 0A3
Date of Revision:
June 3, 2020
Submission Control No.: 230132
2
NAME OF DRUG
CALCIMAR
®
(Calcitonin-Salmon)
THERAPEUTIC OR PHARMACOLOGICAL CLASSIFICATION
Synthetic Salmon Calcitonin
ACTIONS
CALCIMAR
participates in the regulation of the homeostasis of calcium by acting
primarily on the
bone; in Paget's disease presumably by an initial blocking effect on
accelerated bone resorption.
The rate of bone turnover appears to be decreased.
CALCIMAR participates in the regulation of urinary excretion of
phosphate and calcium.
Administration of CALCIMAR decreases the volume and acidity of the
gastric juice and decreases
the volume as well as trypsin and amylase content of the pancreatic
juice.
(For further details see Clinical Pharmacology section).
INDICATIONS
1.
Paget's Disease:
Treatment of symptomatic Paget's disease, only in patients who do not
respond to alternative
treatments or for whom such treatments are not suitable.
2.
Hypercalcemia:
Early treatment of hypercalcemic emergencies, along with other
appropriate agents, when a
rapid decrease in serum calcium is required, until more specific
treatment of the underlying
disease can be accomplished. It may also be added to existing
therapeutic regimens for
hypercalcemia such as intravenous fluids and furosemide, oral
phosphate or corticosteroids, or
other agents. Calcitonin may be used in patients with azotemia and
those with limited cardiac
reserve in whom intravenous fluids may be contraindicated.
Due to evidence of an increased risk of malignancies with the long
term calcitonin use, the
treatment duration should be limited to the shortest period of time
possible and using the minimum
effective dose.
3
CONTRAINDICATIONS
Patients who are hypersensitive to CALCIMAR or to any ingredient in
the formulation or
component of the container. For a complete lis